This analysis demonstrated significant variability in medical policy determinations and evidence cited for clinically relevant pharmacogenetic tests among major US health insurers and laboratory benefit managers.
Chad Moretz, ScD
Advertisement
Articles by Chad Moretz, ScD
This retrospective cohort study in a Medicare Advantage population posits that type 2 diabetes mellitus complications pose an excess burden on healthcare resource use and related costs.
Advertisement
Latest Updated Articles
Medical Policy Determinations for Pharmacogenetic Tests Among US Health PlansPublished: February 10th 2025 | Updated:
- Relationship of Diabetes Complications Severity to Healthcare Utilization and Costs Among Medicare Advantage Beneficiaries
Published: February 13th 2015 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
A "One-Two Punch" to Innovation? The Most Favored Nation Order and Broader US Drug Pricing Reform
2
Telemedicine Boosts Quality of Life, Inhaler Technique for Severe COPD
3
New Partnership Model Boosts Maternal Outcomes in Medicaid ACOs
4
Bispecific Antibodies in Multiple Myeloma Are Moving From Clinical Trials to Community Practice
5
